The latest move follows Pfizer's decision in December to separate its consumer-health business in a joint venture with GlaxoSmithKline. (Photo: AP)
Pharmaceutical behemoth Pfizer Inc. has transformed itself under new leadership through a series of spinouts and joint ventures, mitigating risk by placing some units at arm's length while continuing to reap rewards from them.
Chief Executive Officer Albert Bourla, 57, who took the helm in January after serving as the drugmaker's operations chief, has rapidly transformed the company through a new deal-making strategy. His next major step is a plan to combine Pfizer's less-lucrative off-patent drug business with Mylan NV to form a generic-drug giant.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
